S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$4.45
-0.03 (-0.67 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.41
Now: $4.45
$4.55
50-Day Range
$4.00
MA: $4.21
$4.55
52-Week Range
$2.21
Now: $4.45
$22.00
Volume278,821 shs
Average Volume538,660 shs
Market Capitalization$41.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

MarketRank

Overall MarketRank

0.90 out of 5 stars

Medical Sector

904th out of 1,556 stocks

Diagnostic Substances Industry

19th out of 28 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABIO
CUSIPN/A
Phone720-940-2200
Employees13

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.77 per share

Profitability

Net Income$-5,480,000.00

Miscellaneous

Market Cap$41.47 million
Next Earnings Date2/16/2021 (Estimated)
OptionableNot Optionable
$4.45
-0.03 (-0.67 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

How has ARCA biopharma's stock been impacted by Coronavirus (COVID-19)?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABIO stock has increased by 32.4% and is now trading at $4.45.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than ARCA biopharma?

Wall Street analysts have given ARCA biopharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ARCA biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for ARCA biopharma
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) released its earnings results on Monday, November, 2nd. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.51) by $2.18.
View ARCA biopharma's earnings history
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decline in short interest in December. As of December 31st, there was short interest totaling 41,100 shares, a decline of 17.5% from the December 15th total of 49,800 shares. Based on an average trading volume of 539,500 shares, the short-interest ratio is presently 0.1 days.
View ARCA biopharma's Short Interest
.

Who are some of ARCA biopharma's key competitors?

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 75, Pay $296.15k)
  • Mr. Thomas A. Keuer, Chief Operating Officer (Age 61, Pay $304.02k)
  • Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 61, Pay $290.16k)
  • Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 58)
  • Dr. Debra Marshall FACC, M.D., Chief Medical Officer

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $4.45.

How big of a company is ARCA biopharma?

ARCA biopharma has a market capitalization of $41.47 million. ARCA biopharma employs 13 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is arcabio.com.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.